Fixing Psychiatric Research At A University
By Ed Silverman,
Pharmalot
| 03. 20. 2013
[Op-Ed]
Over the past few years, University of Minnesota bioethicist Carl Elliott has explored a complicated and increasingly controversial episode over a clinical trial and a suicide. The saga has involved researchers at his own university, a major drugmaker, allegations of misconduct, a lawsuit and various investigations. But answers to questions continue to raise more questions, so he has initiated an online petition asking the Minnesota governor to probe his employer. He explains why…The University of Minnesota has turned me into an activist against it. Let me confess right away that this is not a role for which I am naturally suited. I have never staged a protest or addressed a rally. Nor have I ever marched with a sign. On the occasions when I am required to give public lectures, I sweat nervously and display an embarrassing tendency to pause in mid-sentence for uncomfortably long periods. But even I can work up a pretty good head of anger when I see cruelty or injustice, and this is especially true when the injustice is deliberately inflicted and the victim cannot...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...